TOP TEN perturbations for 40048_at (Homo sapiens)

Organism: Homo sapiens
Gene: 40048_at
Selected probe(set): 201166_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 40048_at (201166_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

echinomycin study 1 / deferoxamine study 5

Relative Expression (log2-ratio):-5.5155506
Number of Samples:3 / 3
Experimental echinomycin study 1
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

actinomycin D study 1 / mannitol treated A549 cell sample

Relative Expression (log2-ratio):-3.6835108
Number of Samples:3 / 3
Experimental actinomycin D study 1
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. ATC code:
Control mannitol treated A549 cell sample
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture.

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-2.7354069
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-2.210061
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):2.1740723
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):2.0365353
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 4 (A/H1N1) / mock infected A549 cell sample

Relative Expression (log2-ratio):-1.9108915
Number of Samples:3 / 6
Experimental influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.
Control mock infected A549 cell sample
Human A549 carcinoma cells mock infected (A/H1N1). Sample was taken at 0 hours post-infection.

plicamycin study 1 (100 nM) / vehicle (PBS) treated TC-32 cell sample

Relative Expression (log2-ratio):-1.8164406
Number of Samples:3 / 3
Experimental plicamycin study 1 (100 nM)
TC-32 Ewing´s sarcoma cells treated with compound: plicamycin (mithramycin, 100 nM) for 6 hours. ATC code:
Control vehicle (PBS) treated TC-32 cell sample
TC-32 Ewing´s sarcoma cells treated with 0.01% phosphate-buffered saline (PBS) in growth medium for 6 hours.

R547 study 1 (6h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-1.7737417
Number of Samples:4 / 4
Experimental R547 study 1 (6h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours.

R547 study 3 (6h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-1.712882
Number of Samples:4 / 4
Experimental R547 study 3 (6h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at an IC90 concentration of IC90 = 1.7 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours.